Chair and Member of the Operations Management Committee
Johnson & Johnson
Michelle Brennan is Company Group Chair for Johnson & Johnson Medical Devices Companies, the world’s largest medical technology business. She is responsible for the company’s Medical Device businesses in Europe, Middle East & Africa (EMEA), which includes surgical technology, orthopedics, cardiovascular and specialty solutions directed at delivering clinical and economic value to healthcare systems worldwide.
During Michelle’s 29-year tenure with Johnson & Johnson, she has held a variety of senior executive positions with increasing responsibility across all three sectors of the organization (consumer healthcare, medical devices, and pharmaceuticals) in North America and EMEA, including sales, marketing, enterprise standards & productivity, and management roles. While leading the Ethicon Endo-Surgery business in EMEA between 2009 and 2012, Michelle established her profound knowledge of the region. Before assuming her current role in September 2015, Michelle was President, Enterprise Standards & Productivity, focused on building Global Business Services for Johnson & Johnson.
Delivering quality and meaningful healthcare has remained a passion throughout Michelle’s career. She currently serves as a Board Member of the European medical device trade association, MedTech Europe, demonstrating her commitment towards developing multi-stakeholder partnerships that lead to meaningful health outcomes for patients.
Michelle holds a Bachelor of Science degree in business management from the University of Kansas. In 1999, the YWCA of New Jersey honored her with its Women in Business Achievement award.
Rob ten Hoedt
Vice-Chair and Member of the Operations Management Committee
Rob ten Hoedt is Executive Vice President & President, Europe, Middle East & Africa (EMEA) and a member of Medtronic’s Executive Committee. Mr. ten Hoedt has been with Medtronic since 1991 and has over 25 years of experience in the medical device industry. Leading up to this position, he has held several different leadership roles in Medtronic. He led the CardioVascular business for Europe & Central Asia and the Gastro-Uro business on a global basis before which he ran the wholly-owned Medtronic subsidiary Company, Vitatron. Prior to Medtronic, he held different positions in medical technology companies such as Arjo Hospital Equipment and Polystan Benelux; and also ran his own Distributor Company for several years. He is the Vice-Chairman of the Board of MedTech Europe, the Association representing the medical technology industry in Europe. Rob holds a degree in Commercial Economy from the H.E.A.O. and a Masters in Marketing from the NIMA Business School in the Netherlands.
Vice-Chair and Member of the Operations Management Committee
Dr. Jürgen Schulze became a board member of EDMA in 2003 and was elected as the Association's President in 2009. Beside his board position in MedTech Europe he is also on the board of the German National Association VDGH since 1997 and has been elected President from 2007 to 2009.
Dr. Schulze is the CEO and President of SYSMEX Europe, Middle East and Africa and an Executive Officer of SYSMEX CORP (Japan) after having held several other positions in SYSMEX since 1995.
Prior to joining Sysmex, he has held several business functions in the IVD industry, mainly linked to Merck AG and Bayer Diagnostics, both in Europe and the USA.
Vice-Chair and Member of the Operations Management Committee
Kerstin Wagner is General Manager Laboratory Diagnostics Central Europe, Russia, Middle East and Africa and represents Siemens Healthcare. Kerstin has more than 20 years of experience in the IVD field. Throughout her career at Siemens and former Dade Behring she has held several leading positions in product line management, global marketing and global customer management before being appointed General Manager Laboratory Diagnostics on October 1, 2015.
Treasurer and Member of the Operations Management Committee
BVMed – B. Braun
Dr Meinrad Lugan has a university degree in chemistry (Dipl. Chem.), as well as a PhD in organic chemistry (Dr. rer. nat.), both from the University of Freiburg (Institute for Organic Chemistry and Biochemistry, Prof. Prinzbach). He has held numerous positions including: Director of R & D and Director of International Business Development (BUCK System GmbH), Technical Director (BUCK Environmental LLC), Vice President (BUCK CMI Asia), and CEO (MCG Metall-Chemie Goerrig GmbH & Co KG).
Since 2000 he is Member of B. Braun Group Managing Board (Vorstand), Division OPM (Out Patient Market), and in 2004 also became Member of B. Braun Group Managing Board (Vorstand), Division HC (Hospital Market).
Since 2006 he is Member of the Board of BVMed (Bundesverband Medizintechnologie e. V., Berlin) and in 2007 he became Chairman of the Board. Also since 2006 he is Member of the Board of Eucomed.
Born in 1964, Dr Lugan is married with one son.
Member of the Operations Management Committee
SIDIV - Stago
Medical Biologist & Pharmacist, I work in the IVD industry since 1981 after 5 years spent in the Paris hospitals. I have had the chance to know a diversified career : head of international marketing & sales, head of R&D, head of Production but also several positions of General Manager . Today in charge of Public Affairs.
In parallel I am active in professional associations for 10 years among those : EDMA vice-President ( 2010-2016). I was also one of the 6 members preparing during 3 years the birth of the new MedTech association. Presently I am a MedTech board member representing the French association SIDIV, but also member of the MedTech Operating Management Committee ( OMC ) selecting the topics for the executive board.
Board Member and Member of the Operations Management Committee
Philippe Jacon joined Cepheid in January 2013. In his role as Senior Vice President, Global Access, he leads the company strategy to ensure access to our molecular diagnostic tests globally, (Xpert®MTB/Rif, Xpert®HIV-1 VL, Xpert® HIV Qual, Xpert® HCV, Xpert® HPV, etc.) including to the populations in need in low and middle-income countries that benefit from our concessional prices. All these tests are run on the polyvalent GeneXpert system, that will soon be extended with the new generation portable GeneXpert Omni, allowing further decentralization of molecular testing. Philippe is the focal point of Cepheid to Global Health organizations, with strong interactions at the programmatic level.
Prior to Cepheid, Philippe Jacon hold the position of CEO of the Foundation for Innovative New Diagnostics (FIND)since October 2011.
Philippe Jacon joined FIND from EDMA (European Diagnostic Manufacturers Association) where he acted as the Director General ad interim since March of 2011. Philippe is still on the Board and the Operating Management Committee of Medtech Europe.
Prior to EDMA, he spent most of his career with BD (Becton Dickinson and Co) in various positions and locations. Most notably, he was Worldwide President of BD Diagnostics-Diagnostic Systems and Worldwide President of BD Diagnostics - Microbiology Systems both positions based in Baltimore, MD.
Philippe Jacon has a Microbiologist Engineer degree from the Université de Bretagne Occidentale in France
Greg Ahlberg is Vice President, Abbott Diagnostics EMEA. He was appointed to his current position in August 2017. Previously, Mr. Ahlberg served as Vice President, Abbott Diagnostics United States.
Mr. Ahlberg joined Abbott in 1988 and has worked in various roles of increasing responsibility in finance, manufacturing and sales.
He earned a B.Sc. in Finance Indiana University and an M.B.A. from Kellogg School of Management, Northwestern University.
Ian Bell has been EMEA Regional President for Alcon since joining Novartis / Alcon in March 2016.
Prior to serving in this role Ian was EMEA Regional President for Hospira overseeing a significant expansion in the business as the company expanded and launched its biosimilar portfolio and stabilized its device and generic businesses.
Previously, Ian served as Asia Pacific Regional President for Allergan Inc. based in Singapore for over 7 years and successfully led a rapid expansion of the business with significant investments made in building the resources, process and infrastructure required to grow in emerging and established markets. Prior to this, Ian spent 12 years with GlaxoSmithKline in roles of increasing seniority across Sales and Marketing.
Ian graduated in 1991 with a bachelor’s degree in Economics from York University in the United Kingdom.
Nicolas has spent all his carrier at BD. He led several Business Units (BU) in different countries and regions. He started his carrier as IT project manager and then moved 4 years to the US at the BD WW HQ for a global project. He managed different functions for the Pharmaceutical BU and was in charge to build a new manufacturing plant in Hungary. Since October 2016 he is the BD France VP/GM and BD France SAS President.
Smith & Nephew
Over his 26 years in the Medical Device Industry, Massimiliano has held a number of national and international roles, working for Johnson&Johnson and Smith& Nephew. The most recent and significant experiences have been:
President Europe and Canada at Smith & Nephew – based in Baar (Switzerland),Senior Vice President Asia Pacific at Smith&Nephew – based in Singapore,Senior Vice President Emerging Market at Smith&Nephew – based in Dubai, Regional Managing Director Central & Eastern Europe at Johnson&Johnson – based in Prague, Managing Director Mediterranean Region at Johnson&Johnson –based in Rome.
In terms of experience as a member of Industry Associations or similar organizations, Massimiliano has been:
Board Member ApacMed, Board Member CzechMed (Czech Republic), Board Member American Chamber of Commerce (Czech Republic), Member of British Chamber of Commerce (Singapore).
Massimiliano, (49) is Italian and lives in Wollerau (Switzerland) with his wife Antonella and their 2 sons Edoardo and Alessandro
Claude joined Thermo Fisher Scientific in September 2016 as President of the Microbiology Division (MBD).
Claude has over 20 years’ global experience working in biosciences and the medical devices markets beginning her career with Becton, Dickinson & Company (BD) in marketing and sales before moving into general management and senior global leadership positions. She is a growth-orientated leader who expands the business agenda to set a bold vision and enables a focus and drive in innovation in all the businesses she has led.
Prior to joining Thermo Fisher, Claude served as the Worldwide President for Becton, Dickinson & Company (BD), heading up the Biosciences division for 4 years (USA), and prior to that the Pharmaceutical Systems division of BD in France. Claude led two acquisitions and the entry of BD to the all therapy market.
As a passionate advocate of corporate diversity and women’s leadership, Claude led the BD Women’s Leadership Group having been appointed the W.I.N. (Women in Network) Executive Sponsor and served as the BD European Diversity Leader (2006 & 2009).
Claude holds a Master’s in Medical Management from Ecole Superieure de Commerce de Paris, France and received her Diploma in Biotechnology from the University of Grenoble, France.
Peter hosts the industry Secretariat for the formal UK government engagement mechanism, the Ministerial Medical Technology Strategy Group (MMTSG), jointly chairs NHS England’s MedTech and Diagnostics Board and is a member of the Board of the Government’s HealthTech and Medicines Knowledge Transfer Network. He has also been involved in numerous roles to establish and lead England’s 15 Academic Health Science Networks which were formed in 2013, and in 2014 chaired the health economy workstream of the London Health Commission, set up by the city’s Mayor and Professor The Lord Darzi from Imperial College.
In 2013/14, he was the Chair of the Small Business Research Initiative (SBRI), connecting public sector challenges with solutions from industry, and thereby demonstrating the value of investing money from the NHS to support innovation by the MedTech sector.
Peter has been elected as a Vice Chair of Eucomed, Board Member of MedTech Europe and leads MedTech Europe’s National Association Network.
Internationally, Peter is engaged with government on many levels to promote UK plc and assist companies to export. He is currently working on initiatives in this regard with the US State of Texas.
Peter has 35 years experience in sales, marketing and general management in the UK and across Europe and as a non-executive director of early stage companies.
Roche Diagnostics Ltd.
Michael Heuer entered Roche Diagnostics Manneheim as Product Manager Immunoassays in 1983. Throughout his career with Roche, he has held different leading Marketing and Sales positions in Germany and the United States, before being appointed Head of the Roche Near Patient Testing Business Area in Austria in 2001. From 2004 to 2007, he was Head of the EMEA Subregion-1 covering Central and Eastern Europe, Turkey, Greece and South Africa. He currently heads the EMEA-LATAM Diagnostics Region (Europe, Middle East, Africa and Latin America) within Roche Diagnostics.
Tied with the MedTech for more than 25 years. For last 20 years, the owner of a SME that distributes laboratory and iVD devices to medical market niches for human, and veterinary and plant diseases Labs. Charter member of Polish iVD Association( IPDDL) and for the last 15 years Director General.
Presently Board Member and CEO. In the past member of the EDMA Regulatory and Public Affairs Committees. For two cadency member of EDMA Internal Audit. Since more than 10 years involved in development LabTestsOnLine and MedicalLab multinational web portals cooperation to increase patients and society knowledge about laboratory tests. Leading the National Compliance Group for successful implementation of the MedTech Code of Ethic in 2016.
From the beginning (2012) until successful implementation(2017) working on the Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on in vitro diagnostic medical devices.Recently takes new challenges in HTA area. Graduated from Warsaw Technical University and Postgraduate Studies in Management and Foreign Trade at the Warsaw School of Economics.
Philipp Lindinger is Managing Director of AUSTROMED since 2010. He has also been appointed as the Spokesman for “Initiative Wund?Gesund!” and acts as a Board Member for the ÖGBMT (Austrian Society for Biomedical Technique). Additionally, he is a Member of two Committees for Medical Technology at AS, the Standards Institute of Austria.
Philipp has been recently elected Chairman of the National Association Committee (NAC) of MedTech Europe starting 2018, working intensively to improve the collaboration of the National Associations from MedTech Europe with regards to the European topics. In addition he was elected Board Member of MedTech Europe for the period 2018-2020.
For ten years Philipp worked with Herba Chemosan Apotheker-AG, Austria’s largest pharmaceutical wholesale company, in Organization and Logistics, and then later became the Assistant to the Board of Directors. Afterwards he worked at Sanova Pharma GesmbH as Business Unit Director for Logistics during five years prior to joining AUSTROMED.
Katarzyna Mazur-Hofsaess was appointed President EMEA at Zimmer Biomet after the close of the merger in June 2015, having held this position since April 2013 at Zimmer. Dr. Mazur-Hofsaess joined Zimmer in February 2010 as Senior Vice President, EMEA Recon.
She has more than 20 years’ experience within the pharmaceutical, diagnostics and medical device sectors. Prior to joining Zimmer, Dr. Mazur-Hofsaess served in various management positions at Abbott Laboratories from 2001, most recently as Vice President, Diagnostics – Europe. She is a qualified Medical Doctor and also holds a Ph.D. from Gdansk Medical University, as well as an MBA from the Warsaw School of Economics and the University of Minnesota.
Yasha MITROTTI, Colombian native and Italian by adoption, graduated as an industrial engineer from the university of the Andes in Bogotá (Colombia, 1996) after an academic curriculum in France, in the United States and in Colombia.
He joined bioMérieux in Colombia in 1997, where he held several commercial functions before being named Country Manager of the subsidiary in 2000. After spending 6 years in Colombia, he has been successively Country Manager in Brazil, Latin America Executive Director, Country Manager in Italy, Commercial Operations VP Europe and Corporate VP Europe Middle East Africa (EMEA).
Since July 2015, the scope of his missions also encompasses the Global Commercial Performance.
Stuart joined Stryker in 2008 as Managing Director of France. He subsequently assumed the role of Managing Director for Southern Europe and Joint Preservation Europe. Since July 2015 he took over the role of President of Europe with the main focus to drive the implementation of Stryker’s Transatlantic Operating Model through the eight divisions that comprise the product portfolio of Stryker. With effect from January 2017 he became responsible for both EMEA & Latin America.
Prior to Stryker, Stuart worked in the electronics industry with Premier Farnell and logistics with CHEP. In both companies, he held a variety of managerial roles throughout Europe and Latin America. Stuart is a graduate in Management Studies at the University of Leeds.
Bachelor of Biology (University of Barcelona). Master in Alimentary Biotechnology for ETSIB (Superior Technical School of Engineers from Barcelona), Executive MBA for INESE and Superior Course of Organization and commercial Direction for the Chamber of Trade of Madrid.
During lasts years Carlos has occupied positions of responsibility in marketing and sales as well as commercial management in several divisions in different companies of the sector of sanitary technology (Product Manager in Roche Diagnostics S.L., Business Unit Manager in Bayer Diagnostics S.L., Division Check Up Manager in Menarini Diagnostics S.L and Sales and Marketing Manager in Dade Behring S.A.)
He is married with three children.
Carlos joined FENIN 17 years ago as Director of the Barcelona office along and Secretary of IVD Sector and Secretary of Technology and Clinical Information Systems Sector
Dr. Martin Walger is managing director of the German IVD Association VDGH , representing 100 members companies (IVD- and Life Science Research Industry). He joined VDGH in 2008.
From 1995 to 2008 Martin Walger has been serving as director Personnel and Hospital organization for the German Hospital Federation DKG. From 1993 to 1995 he worked for the Bundesknappschaft, part of the German statutory health insurance. Previously he did research at the Center for Labour and Social issues (ZENTRAS). He is holding a degree in economics from the University of Trier, Germany.
Born in 1962, Martin Walger is married with three children.